hematologic malignacy
Conditions
Interventions
Group 1:anti-HBc(-)anti-HBs(-)
Group 2:anti-HBc(-)anti-HBs(+)
Group 3:anti-HBc(+)anti-HBs(-)
Group 4:anti-HBc(+)anti-HBs(+)
Sponsors
the First Affiliated Hospital of Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
No minimum to 60 Years
Inclusion criteria
Inclusion criteria: 1. The informed consent is signed by the subjects or their legal representatives before the start of clinical research; 2. Male and female patients,and the female patients with negative pregnancy test; 3. aged younger than 60 years old; 4. Hematological malignancy patients with HBsAg negativity and can't detect HBV-DNA in peripheral blood who undergo allogeneic hematopoietic stem cell transplantation; 5. ECOG physical status score 0~2 score; 6. No major organ dysfunction.
Exclusion criteria
Exclusion criteria: 1. Patients with severe liver and renal function and heart and lung dysfunction; 2. An uncontrolled or severe infection; 3. Hematological malignancy patients with HBsAg postive or detecting HBV-DNA in peripheral blood bofore allogeneic hematopoietic stem cell transplantation,or the hematopoietic stem cell donor with HBsAg postive or detecting HBV-DNA in peripheral blood; 4. ECOG performance status >2; 5. second tumour; 6. severe neurologic and psychiatric disorder interfering with the ability to consent on the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative incidence of HBV reaction;overall survival;disease-free survival;cumulative replase rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| nonreplase mortality;the incidence of acute GVHD and chronic GVHD; | — |
Countries
China
Contacts
Public ContactHuang He
the First Affiliated Hospital of Zhejiang University School of Medicine
Outcome results
None listed